Safety and Effectiveness Study of DragonFly-T System for Severe Tricuspid Regurgitation

Last updated: July 18, 2024
Sponsor: Hangzhou Valgen Medtech Co., Ltd
Overall Status: Active - Recruiting

Phase

N/A

Condition

Congestive Heart Failure

Treatment

Medical therapy

DragonFly-T Transcatheter Tricuspid Valve Repair System

Clinical Study ID

NCT05556460
DF-VL-03
  • Ages > 18
  • All Genders

Study Summary

The primary objective of this trial is to demonstrate the safety and effectiveness of the DragonFly-T system in improving clinical outcomes in symptomatic patients with severe tricuspid regurgitation (TR), who are at intermediate or greater estimated risk for mortality or morbidity with tricuspid valve surgery. This randomized controlled trial will compare the investigational device (DragonFly-T system) to Control (Medical Therapy).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥ 18 years

  2. In the judgment of the local cardiac team, the patient has been adequately treatedaccording to applicable standards (including medical management)and has been stablefor at least 30 days.

  3. Despite the drug optimization treatment according to the above method, patientsstill have symptoms of TR;

  4. Determined by the local cardiac team to be at intermediate or higher risk fortricuspid valve surgery

  5. New York Heart Association (NYHA) Cardiac function Class II-IVa;

  6. The patient is suitable for transcatheter tricuspid valve repair, suitable for theuse of this study instrument, and the femoral vein access is feasible and canaccommodate catheter; 6. Patient must provide written informed consent before anysteps related to the study.

Exclusion

Exclusion Criteria:

  1. Tricuspid valve leaflet anatomy, which may preclude clip implantation, proper clippositioning on the leaflets, including but not limited to the following:

  2. Evidence of calcification in the grasping area;

  3. Presence of a severe coaptation defect of the tricuspid leaflets;

  4. Severe leaflet defect(s) and cleft preventing proper device placementdetermined by ECL;

  5. Epstein anomaly.

  6. Other serious heart valvular diseases requiring intervention or planning tointervention in the next 12 months; Note: If mitral and tricuspid valve lesions arecombined, mitral valve surgery can be performed first, and re-evaluation can beperformed 60 days after surgery.

  7. Tricuspid stenosis evaluated by ECL and/or cross-tricuspid differential pressure ≥ 5mmHg;

  8. Previous tricuspid valve surgery or transcatheter therapy;

  9. Echocardiography suggested intracardiac thrombus, tumor or mass, or femoral vein andinferior vena cava implants or thrombus;

  10. TTE and TEE are unable to evaluate tricuspid valve anatomy; Participated in any drugand/or medical device clinical trials within 1 month prior to the trial; ......

  11. The researchers do not consider it appropriate to be enrolled in the study.

Study Design

Total Participants: 236
Treatment Group(s): 2
Primary Treatment: Medical therapy
Phase:
Study Start date:
August 15, 2024
Estimated Completion Date:
December 15, 2027

Study Description

A Prospective, Multicenter, Parallel, Randomized Controlled Study to Evaluate the Safety and Efficacy of the DragonFly-T Transcatheter Tricuspid Valve Clip System in the Treatment of Tricuspid Regurgitation. After signing the informed consent form, participants in the experimental group will be treated with the Dejin Medical DragonFly-T Transcatheter Tricuspid Valve Clip System and continue receiving medical therapy as determined by the investigator. Participants in the control group will continue to receive medical therapy as determined by the investigator. Control group participants are allowed to cross over to the experimental group after completing the 12-month follow-up. All participants will undergo clinical follow-up before discharge (not applicable to control group participants), at 30 days post-treatment, 6 months post-treatment, 12 months post-treatment, and annually at 2, 3, 4, and 5 years..

The primary endpoint is the hierarchical composite endpoint formed by all-cause mortality or tricuspid valve reintervention, heart failure hospitalization, and KCCQ improvement at 12 months post-treatment.

To evaluate the safety and effectiveness of the Valgen Medtech DragonFly-T Transcatheter Tricuspid Valve Repair System in the treatment of patients with severe tricuspid regurgitation (TR), who are at intermediate or greater estimated risk for mortality or morbidity with tricuspid valve surgery.

Connect with a study center

  • West China Hospital of Sichuan University

    Chengdu, Sichuan
    China

    Active - Recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang 310000
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.